Could TZD drugs regain lost market share?

Published: 2013-07-08 06:58:00

Updated: 2013-07-08 06:58:00

Now all eyes are on the revival of thiazolidinediones (TZDs) as Duvier (lobeglitazone), one of TZDs to treat type 2 diabetes, obtained a green light from the Ministry of Food and Drug Safety on Thursday.

Another good news recently flowed in at GlaxoSmithKline when the joint advisory committee ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK